AbbVie Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
2025.11.20 21:31
portai
I'm PortAI, I can summarize articles.

AbbVie Inc.'s stock fell 1.49% to $229.45 on Thursday, marking its third consecutive day of losses. The stock closed 6.27% below its 52-week high. In comparison, Johnson & Johnson rose 0.28%, while Pfizer and Amgen fell 1.93% and 1.85%, respectively. Trading volume was 1.9 million below the 50-day average. The S&P 500 and Dow Jones also experienced declines.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) shed 1.49% to $229.45 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 1.56% to 6,538.76 and Dow Jones Industrial Average falling 0.84% to 45,752.26. This was the stock's third consecutive day of losses. AbbVie Inc. closed 6.27% below its 52-week high of $244.81, which the company reached on October 1st. The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) rose 0.28% to $203.07, Pfizer Inc. (PFE) fell 1.93% to $24.40, and Amgen Inc. (AMGN) fell 1.85% to $336.07. Trading volume (4.2 M) remained 1.9 million below its 50-day average volume of 6.1 M. Data source: Dow Jones Market Data, FactSet. Data compiled November 20, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 11-20-25 1631ET
Source: Dow Jones The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.